Elicera Therapeutics AB Logo

Elicera Therapeutics AB

Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.

ELIC | ST

Overview

Corporate Details

ISIN(s):
SE0015382080 (+1 more)
LEI:
549300I35L0R4INBFG27
Country:
Sweden
Address:
C/O Elicera Therapeutics AB, 402 24 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elicera Therapeutics AB is a clinical-stage immuno-oncology company that develops cell and gene therapies for immune-based cancer treatments. The company's work focuses on two core technology areas: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. Elicera's key asset is the proprietary iTANK (Immuno-Oncology Targeting and Killing) technology platform, a universal solution designed to enhance the efficacy of any CAR T-cell therapy by enabling a multi-targeted immune attack, particularly against solid tumors. The company's pipeline includes four drug candidates, with its oncolytic virus (ELC-100) and CAR T-cell therapy (ELC-301) in or entering clinical phase I/II trials for neuroendocrine tumors and B-cell lymphoma, respectively.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Margareth Jorvid Other Other 21,700 40,145.00 SEK

Peer Companies

Company Country Ticker View
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom PSY
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland PUR
Puretech Health PLC Logo
A clinical-stage biotherapeutics company developing new medicines for devastating diseases.
United States of America PRTC
PZ Cormay S.A. Logo
Manufactures and distributes IVD reagents and analyzers for human and veterinary medicine.
Poland CRM
Quantum Genomics Logo
Biopharma developing cardiovascular treatments, now in judicial liquidation.
France ALQGC
Quratis Inc. Logo
Develops infectious disease vaccines and offers biologics CDMO services for global health.
South Korea 348080
Recordati Industria Chimica e Farmaceutica Logo
Global pharma group developing drugs for common/rare diseases & supplying APIs worldwide.
Italy REC
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel REKA
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden RESP

Talk to a Data Expert

Have a question? We'll get back to you promptly.